[go: up one dir, main page]

SG11202004863QA - Zika vaccines and immunogenic compositions, and methods of using the same - Google Patents

Zika vaccines and immunogenic compositions, and methods of using the same

Info

Publication number
SG11202004863QA
SG11202004863QA SG11202004863QA SG11202004863QA SG11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA SG 11202004863Q A SG11202004863Q A SG 11202004863QA
Authority
SG
Singapore
Prior art keywords
methods
same
immunogenic compositions
zika vaccines
zika
Prior art date
Application number
SG11202004863QA
Inventor
Jill A Livengood
Hansi Dean
Htay Htay Han
Raman Rao
Jackie Marks
Gary Dubin
Moerlooze Laurence De
Hetal Patel
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/059227 external-priority patent/WO2019090233A2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG11202004863QA publication Critical patent/SG11202004863QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/22—Testing for sterility conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/74—Optical detectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202004863QA 2017-11-30 2018-11-30 Zika vaccines and immunogenic compositions, and methods of using the same SG11202004863QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059227 WO2019090233A2 (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
PCT/US2018/059233 WO2019090238A1 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
PCT/US2018/063369 WO2019108970A1 (en) 2017-11-30 2018-11-30 Zika vaccines and immunogenic compositions, and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202004863QA true SG11202004863QA (en) 2020-06-29

Family

ID=66664221

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202003975WA SG11202003975WA (en) 2017-11-30 2018-11-30 Method for inactivating zika virus and related methods
SG11202004863QA SG11202004863QA (en) 2017-11-30 2018-11-30 Zika vaccines and immunogenic compositions, and methods of using the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202003975WA SG11202003975WA (en) 2017-11-30 2018-11-30 Method for inactivating zika virus and related methods

Country Status (11)

Country Link
US (4) US20210403879A1 (en)
EP (2) EP3717511A4 (en)
JP (4) JP2021505549A (en)
KR (2) KR20200090893A (en)
CN (4) CN111527104A (en)
AU (5) AU2018375789B2 (en)
BR (2) BR112020010466A2 (en)
CA (2) CA3084605A1 (en)
MX (2) MX2020005554A (en)
SG (2) SG11202003975WA (en)
WO (2) WO2019108970A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN111527104A (en) 2017-11-30 2020-08-11 武田疫苗股份有限公司 Zika vaccine and immunogenic compositions and methods of use thereof
WO2020017765A1 (en) * 2018-07-18 2020-01-23 (주)진매트릭스 Zika virus variant and zika vaccine composition comprising same
US20220211836A1 (en) * 2019-05-08 2022-07-07 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
RU2717993C1 (en) * 2019-10-22 2020-03-27 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Method of producing antigen of zika virus, having immunogenic and antigenic properties
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
US20240287544A1 (en) * 2023-02-06 2024-08-29 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
ES2382946T3 (en) 1997-08-28 2012-06-14 Cj Cheiljedang Corporation Japanese attenuated encephalitis virus
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
RS20070078A (en) 2004-08-27 2008-11-28 Panacea Biotec Ltd., Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
US8865184B2 (en) 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
KR20170124619A (en) 2009-03-27 2017-11-10 아카데미아 시니카 Methods and compositions for immunization against virus
CN101954076A (en) 2009-04-27 2011-01-26 免疫制剂美国公司 The immunotherapy of autoimmune hepatitis and prevention
CN101876650B (en) 2010-07-02 2014-04-09 中国烟草总公司郑州烟草研究院 Method for measuring formaldehyde content in smoke aqueous gel
EA201391515A1 (en) 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. INACTIVATED DENGE VIRUS VACCINE
CN103796676B (en) 2011-06-17 2017-09-12 伯哈拉特生物技术国际有限公司 The vaccine combination of datum hole Kenya Strain comprising inactivation
PL3106176T3 (en) 2011-12-06 2018-03-30 Valneva Austria Gmbh Aluminium compounds for use in therapeutics and vaccines
CN104159603A (en) 2012-03-08 2014-11-19 诺华股份有限公司 Combination vaccines with tlr4 agonists
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
CN102680595A (en) 2012-05-03 2012-09-19 安阳市双环助剂有限责任公司 Method for determining content of free formaldehyde in dispersing agent MF
WO2015059714A1 (en) 2013-09-14 2015-04-30 Bharat Biotech International Limited Emergency mode in a hybrid vehicle
WO2016044023A1 (en) 2014-09-17 2016-03-24 The University Of Iowa Research Foundation Viral rna segments as immunomodulatory agents and vaccine components
US10485862B2 (en) 2014-10-07 2019-11-26 Serum Institute Of India Pvt Ltd Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
US20180185467A1 (en) 2015-06-22 2018-07-05 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
WO2017009873A1 (en) 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
WO2017056094A1 (en) 2015-09-30 2017-04-06 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
MX2018007627A (en) 2015-12-23 2019-02-14 Valneva Austria Gmbh Zika virus vaccine.
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
MX2018009917A (en) 2016-02-17 2019-08-14 Curevac Ag Zika virus vaccine.
US11648303B2 (en) 2016-02-25 2023-05-16 The Trustees Of The University Of Pennsylvania Vaccines against zika virus
WO2017161151A1 (en) 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (en) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 Inactivated Zika virus vaccine
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
JP6843970B2 (en) 2016-05-10 2021-03-17 ナジット テクノロジーズ， インコーポレイテッド Using a double-oxidation process to inactivate pathogens to produce a highly immunogenic inactivated vaccine
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
EP3463445A1 (en) 2016-06-02 2019-04-10 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
BR112018075440A2 (en) 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center compositions and methods for preventing and treating Zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
EP3468590B1 (en) 2016-06-13 2025-01-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
BR112018077041A2 (en) 2016-07-08 2019-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale genomic sequences coding for a mutant-acting Zika virus
WO2018022786A1 (en) 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
EP3541416A1 (en) 2016-11-17 2019-09-25 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503696B (en) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 A Zika virus subunit vaccine expressed in yeast cells
CN108503697B (en) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by drosophila cells
WO2018165373A1 (en) 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
US11286502B2 (en) 2017-06-20 2022-03-29 Texas Tech University System ZIKA virus like particle (VLP) based vaccine and microneutralization assay
EP3417943B1 (en) 2017-06-21 2020-02-12 Eppendorf AG Centrifuge rotor with seal
CN107188935B (en) 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 A kind of zika virus NS1 antigenic mutants and its application
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
CN107537029B (en) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 Zika virus and yellow fever virus combined inactivated vaccine
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019090228A2 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2019104157A1 (en) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
CN111527104A (en) 2017-11-30 2020-08-11 武田疫苗股份有限公司 Zika vaccine and immunogenic compositions and methods of use thereof
CN108187036A (en) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 A kind of zika virus combines inactivated vaccine with encephalitis B virus
CN108210921A (en) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 A kind of zika virus vaccine and preparation method thereof
US20210087617A1 (en) 2018-02-22 2021-03-25 Nano4 Global, Lda Method for detecting flaviviridae
BR112020018188A2 (en) 2018-03-08 2021-02-02 Codagenix Inc. attenuated flaviviruses
CN112292148A (en) 2018-03-29 2021-01-29 埃默杰克斯疫苗控股有限公司 Vaccine composition
KR102075581B1 (en) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 Adjuvant comprising nucleic acid molecule inserted viral expression regulation sequence and phamraceutical composition having the adjuvant
WO2020017765A1 (en) 2018-07-18 2020-01-23 (주)진매트릭스 Zika virus variant and zika vaccine composition comprising same
JP7320601B2 (en) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 Broad-spectrum anti-influenza vaccine immunogen and its use
EP3870208A4 (en) 2018-10-26 2022-10-26 New York Blood Center, Inc. IMMUNOGENIC ZIKA VIRUS COMPOSITIONS
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
US20220211836A1 (en) 2019-05-08 2022-07-07 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
US20230272405A1 (en) 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
MX2020005554A (en) 2020-10-12
BR112020010466A2 (en) 2020-11-24
AU2022200351B2 (en) 2022-06-23
WO2019108976A1 (en) 2019-06-06
CN111527104A (en) 2020-08-11
CA3084605A1 (en) 2019-06-06
EP3717638A1 (en) 2020-10-07
US20230398199A9 (en) 2023-12-14
MX2020004633A (en) 2020-09-28
AU2022200351A1 (en) 2022-02-17
AU2018375173B2 (en) 2022-08-25
AU2022275515A1 (en) 2023-01-19
JP7443233B2 (en) 2024-03-05
AU2018375789B2 (en) 2021-11-11
WO2019108970A1 (en) 2019-06-06
CN111601885A (en) 2020-08-28
US20240024454A1 (en) 2024-01-25
JP2024001177A (en) 2024-01-09
JP2021505549A (en) 2021-02-18
CN116983398A (en) 2023-11-03
BR112020009960A2 (en) 2020-11-10
US20240285747A1 (en) 2024-08-29
CN116983399A (en) 2023-11-03
US11975062B2 (en) 2024-05-07
AU2022275515B2 (en) 2024-09-26
CA3085016A1 (en) 2019-06-06
JP2021505134A (en) 2021-02-18
US20210106669A1 (en) 2021-04-15
US20210403879A1 (en) 2021-12-30
KR20200090893A (en) 2020-07-29
CN111601885B (en) 2025-01-07
AU2022235577A1 (en) 2022-10-13
AU2018375173A1 (en) 2020-05-28
SG11202003975WA (en) 2020-06-29
JP2023134630A (en) 2023-09-27
EP3717511A4 (en) 2021-09-15
AU2018375789A1 (en) 2020-05-28
EP3717511A1 (en) 2020-10-07
EP3717638A4 (en) 2022-03-09
KR20200094191A (en) 2020-08-06

Similar Documents

Publication Publication Date Title
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
HUS2200035I1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL257800A (en) Vaccine compositions having improved stability and immunogenicity
IL268168A (en) Immunogenic compositions for use in pneumococcal vaccines
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
GB201711635D0 (en) Immunogenic composition
IL269590A (en) Methods and compositions for reduction of immunogenicity
IL251120A0 (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
SG11201803581VA (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use
IL271603A (en) Immunogenic compositions
GB201721582D0 (en) S aureus antigens and immunogenic compositions
IL258700A (en) Adjuvant and vaccine composition containing the same
GB2570806B (en) Immunogenic agent and associated compositions, uses and methods
HK40103030A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40103231A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40030428A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40031534A (en) Zika vaccines and immunogenic compositions, and methods of using the same
HK40030429A (en) Zika vaccines and immunogenic compositions, and methods of using the same
GB201911959D0 (en) Immunogenic compositions and uses therefor
SG11202004167XA (en) Immunogenic compositions and uses therefor
AU2017904540A0 (en) Immunogenic compositions and uses therefor
AU2014902031A0 (en) Immunogenic vaccines and uses thereof